- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2012.
- Why 3/10
- Inlyta is an already-approved, marketed drug with no pending PDUFA date, Advisory Committee, or pivotal readout in the next ~12 months. The next catalysts are patent litigation outcomes and eventual generic entry, but these are not hard dated binary events. Inlyta contributes roughly $923M in annual revenue to Pfizer's $63B+ total, making it a small part of a diversified giant, so even a major change would have limited impact on the stock.
Inlyta is a mature, declining-revenue product with no upcoming binary catalysts. Watch for resolution of patent litigation against Sandoz and Alkem, which will determine the timing of generic entry (currently expected 2027-2028). Any settlement or court ruling on the axitinib patents could accelerate or delay generic competition, but even a major patent loss would have a modest impact on Pfizer's overall revenue given Inlyta's ~$923M annual contribution versus Pfizer's $63B+ total revenue.
Price Chart
Executive Summary
Inlyta (axitinib) is Pfizer's oral VEGFR-targeted kinase inhibitor approved since 2012 for advanced renal cell carcinoma (RCC), both as a single agent after prior therapy and in first-line combinations with avelumab or pembrolizumab. It generated roughly $923 million in 2025 revenue, down 6% year-over-year, reflecting competitive pressure and approaching loss of exclusivity. Sandoz has received tentative FDA approval for a generic version, and Pfizer is engaged in patent litigation against both Sandoz and Alkem to delay generic entry, currently expected in 2027-2028. Inlyta is a small part of Pfizer's diversified $63B+ revenue base, so its individual performance has limited impact on the stock.
How It Works
Inlyta (axitinib) is an oral targeted cancer drug that blocks a family of proteins called vascular endothelial growth factor receptors (VEGFR-1, -2, and -3). These receptors are involved in the growth of new blood vessels that tumors need to get oxygen and nutrients. By inhibiting these receptors, Inlyta starves the tumor by cutting off its blood supply. It is more selective for VEGFR than older similar drugs, which may reduce some side effects.
Trial Status
Inlyta is FDA-approved and commercially marketed. It was initially approved in 2012 for advanced RCC after one prior systemic therapy, and later expanded to first-line use in combination with avelumab (2019) and pembrolizumab. Pfizer continues to study axitinib in combination regimens through investigator-sponsored and company-sponsored trials, including a Phase 3 continued-access study (NCT05059522) estimated to complete in December 2026.
The Two-Sided Case
Upcoming Catalysts
- Resolution of patent litigation against Sandoz (filed Nov 2024, Delaware) could determine generic entry timing.
- Resolution of patent litigation against Alkem (filed May 2026, Delaware) after Pfizer dropped an earlier suit in July 2026.
- Potential generic axitinib launch, currently expected in 2027-2028, which would significantly reduce branded Inlyta sales.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report